Neurogene Inc.

For the period ended Dec 31, 2025. Filed Mar 24, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 24, 2026

NGNE$26.00+2.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders’ Equity

Consolidated Statement of Stockholders’ Equity

Common Stock · AdditionalPaid- InCapital · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Amount · Amount · Amount
Balance- December 31, 2023	12,823,665	$—		$373,178		(187,154)		$186,024
Stock-based compensation expense	—		8,320		—		8,320
Common stock issued upon exercise of stock options	92,653	—		1,676		—		1,676
Shares issued upon the exercise of pre-funded warrants	103,407	—		—		—		—
Issuance of common shares and pre-funded warrants in a private financing, net of $10,501 offering costs	1,835,000	—		189,499		—		189,499
Net loss	—	—		—		(75,144)		(75,144)
Balance- December 31, 2024	14,854,725	$—		$572,673		$(262,298)		$310,375
Stock-based compensation expense	—		14,183		—		14,183
Issuance of common stock in at-the-market offering, net of offering costs	1,200,000	—		30,330		—		30,330
Exchange of common stock for pre-funded warrants	(667,500)	—		—		—		—
Common stock issued upon exercise of stock options	20,735	—		266		—		266
Common stock issued upon vesting of restricted stock units	73,158	—		—		—		—
Common stock issued under Employee Stock Purchase Plan	8,682	—		84		—		84
Net loss	—	—		—		(90,351)		(90,351)
Balance- December 31, 2025	15,489,800	$—		$617,536		$(352,649)		$264,887

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.